SANUWAVE Health, Inc. (SNWV)
| Market Cap | 44.47M -84.4% |
| Revenue (ttm) | 44.02M +12.7% |
| Net Income | 15.26M |
| EPS | 0.78 |
| Shares Out | 8.60M |
| PE Ratio | 6.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,826 |
| Open | 5.07 |
| Previous Close | 5.14 |
| Day's Range | 5.06 - 5.30 |
| 52-Week Range | 3.92 - 36.42 |
| Beta | 1.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About SNWV
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and ch... [Read more]
Financial Performance
Financial StatementsNews
SANUWAVE Health Earnings Call Transcript: Q2 2026
Q2 2026 saw record applicator sales but a sharp decline in system sales due to used device market saturation and industry disruption from CMS reimbursement cuts. Revenue fell 3% year-over-year, with gross margin and profitability pressured. Guidance was withdrawn pending CMS decisions.
SANUWAVE Health Quarterly report: Q2 2026
SANUWAVE Health has published its Q2 2026 quarterly earnings report on August 7, 2026.
SANUWAVE Health Earnings release: Q2 2026
SANUWAVE Health released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
SANUWAVE Health Slides: Q2 2026
SANUWAVE Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Sanuwave Announces Q2 FY2026 Financial Results
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.
Sanuwave Will Host a Conference Call on August 7, 2026 at 8:30 AM (ET) to Present Q2 2026 Financial Results
EDEN PRAIRIE, Minn., July 30, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will ...
Sanuwave Health sees Q2 revenue $9.6M-$9.8M
Sanuwave Health (SNWV) announced that revenues for the second quarter of 2026 are expected to be in the range of $9.6M-$9.8M, above the high end of the revised guidance range…
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6–$9.8 Million, Above High End of Revised Guidance
EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced wo...
SANUWAVE Health Transcript: Planet MicroCap Las Vegas 2026
Wound care is undergoing a payer-driven shift to evidence-based medicine, creating opportunities for high-efficacy, cost-effective solutions. UltraMIST’s strong clinical evidence, expanding reimbursement, and consumables-driven model position it for growth, especially as it targets large enterprise accounts.
Sanuwave Health Updates Second Quarter 2026 Guidance
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June 16,...
SANUWAVE Health Slides: Investor presentation
SANUWAVE Health has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
SANUWAVE Health Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation votes. Quorum was met, voting was conducted online, and results will be disclosed in a Form 8-K. Only meeting-related questions were addressed during the Q&A.
SANUWAVE Health Earnings Call Transcript: Q1 2026
Record Q1 revenue and strong consumables growth were achieved despite a market freeze from CMS pricing changes. Guidance for 2026 remains robust, with expectations for a stronger second half driven by seasonality and large account engagement.
SANUWAVE Health Quarterly report: Q1 2026
SANUWAVE Health has published its Q1 2026 quarterly earnings report on May 13, 2026.
SANUWAVE Health Earnings release: Q1 2026
SANUWAVE Health released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
SANUWAVE Health Slides: Q1 2026
SANUWAVE Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Sanuwave Health reports Q1 EPS (17c) vs (72c) last year
Reports Q1 revenue $9.6M vs $9.3M last year. “The seemingly ubiquitous question in advanced wound care during Q1 was ‘When is the turn coming and when will the recovery start?’”…
Sanuwave Health sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
17:03 EDT Sanuwave Health (SNWV) sees Q2 revenue $11.1M-$11.6M, one estimate $11.5M
Sanuwave Health backs FY26 revenue view $51M-$55M, one estimate $51.35M
17:03 EDT Sanuwave Health (SNWV) backs FY26 revenue view $51M-$55M, one estimate $51.35M
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history.
Sanuwave Will Host a Conference Call on May 13, 2026 at 8:30 AM (ET) to Present Q1 2026 Financial Results
EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will h...
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
SANUWAVE Health Proxy statement: Proxy filing
SANUWAVE Health filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Sanuwave Health narrows Q1 revenue view to $9.6M-$9.7M from $9.6M-$10.3M
Q1 revenue consensus $9.84M. “At the end of Q1 the Company saw several good-sized deals (all of which remain live) slide out of the quarter and this brought us in…
Sanuwave Health price target lowered to $47 from $53 at Roth Capital
Roth Capital analyst Kyle Bauser lowered the firm’s price target on Sanuwave Health (SNWV) to $47 from $53 and keeps a Buy rating on the shares. Despite an FY26 revenue…